Inspire scuttles eye drug and pencils new deal with Allergan

Seven months after reporting that its lead drug failed a late-stage trial, Durham, NC-based Inspire Pharmaceuticals has opted to shelve the dry eye therapy and recalculate its partnership deal with Allergan. Inspire gets back all rights to Prolacria, which proved a disappointment in Phase III and will now go into limbo, with no plans for a new study. And Inspire will get stepped down revenue rates from sales of Restasis and "any other human ophthalmic formulations of cyclosporine owned or...

Inspire Pharma R&D chief departs in shakeup

Inspire Pharmaceuticals' R&D chief is departing the company as the new CEO puts his stamp on the Durham, NC-based developer. Sepracor vet Adrian Adams was recently tapped to run the company, and he wasted little time in shaking up the executive team that runs the biotech. Aside from redefining some roles and planning two new hires, Adams says that R&D chief Benjamin Yerxa will step aside at the end of this month. And a company spokesperson said that Yerxa's decision was driven at least...